The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
Philipp D. le Coutre
Research Funding - Novartis
Heinz Gisslinger
No relevant relationships to disclose
Pierre Zachee
No relevant relationships to disclose
Vikas Gupta
Consultant or Advisory Role - Incyte; Novartis; Sanofi ; YM BioSciences
Honoraria - Incyte; Novartis
Other Remuneration - Incyte; Novartis
Jose Ricardo Perez
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nora Schenk
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Suresh Vutukuru
Employment or Leadership Position - Novartis
Carmen Garcia-Hernandez
No relevant relationships to disclose
Renato Tavares
No relevant relationships to disclose
Monica Bocchia
No relevant relationships to disclose
Dietger Niederwieser
Consultant or Advisory Role - Novartis
Honoraria - Novartis